A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study.
- Citation:
- J Clin Oncol vol 26 (15s) abstr 8080
- Meeting Instance:
- ASCO 2008
- Year:
- 2008
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 884
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- Corr. Author:
- Authors:
- A. A. Adjei S. J. Mandrekar G. K. Dy J. R. Molina D. R. Gandara K. L. Allen Ziegler P. J. Stella K. M. Rowland Jr S. E. Schild R. G. Zinner
- Networks:
- Study
- NCCTG-N0426
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords: